<DOC>
	<DOCNO>NCT01977235</DOCNO>
	<brief_summary>As gene polymorphism uridine diphosphate glucuronosyl transferase 1A1 ( UGT1A1 ) relate side effect diarrhea induce irinotecan . UGT1A1 gene *28 ( 6/6 6/7 ) *6 ( G/G G/A ) relate low probability diarrhea UGT1A1 gene *28 ( 7/7 ) *6 ( A/A ) relate high probability diarrhea . The purpose study find efficacy side effect two different dosage irinotecan combine cisplatin scheme extensive disease-small cell lung cancer UGT1A1 gene *28 ( 6/6 6/7 ) *6 ( G/G G/A ) , base hypothesis UGT1A1 gene *28 ( 7/7 ) *6 ( A/A ) Chinese population increase dose irinotecan improve efficacy without increase side effect patient UGT1A1 gene *28 ( 6/6 6/7 ) *6 ( G/G G/A ) .</brief_summary>
	<brief_title>Two Different Dosages Irinotecan Combined With Cisplatin Scheme Extensive Disease-Small Cell Lung Cancer</brief_title>
	<detailed_description />
	<mesh_term>Lung Neoplasms</mesh_term>
	<mesh_term>Small Cell Lung Carcinoma</mesh_term>
	<mesh_term>Irinotecan</mesh_term>
	<mesh_term>Cisplatin</mesh_term>
	<mesh_term>Camptothecin</mesh_term>
	<criteria>Histologic cytologic diagnosis smallcell lung cancer Extensivestage disease , define disease extend beyond one hemithorax involve contralateral mediastinal , hilar supraclavicular lymph node , and/or pleural effusion . Males females 18 75 year No prior chemotherapy , surgery radiotherapy administer , interval least four week . Performance status 02 ECOG criterion . Expected survival three month . At least one unidimensional measurable lesion meeting Response Evaluation Criteria Solid Tumors ( RECIST . 2000 ) . Patient compliance allow adequate followup . Informed consent patient patient 's relative . Adequate hematologic ( neutrophil count &gt; = 1,500/uL , platelet &gt; = 100,000/uL ) , hepatic ( transaminase = &lt; upper normal limit ( UNL ) x2.5 , bilirubin level = &lt; UNL x 1.5 ) , renal ( creatinine = &lt; UNL ) function The gene type UGT1A1 *28 6/6 6/7 . If female : childbearing potential either terminate surgery , radiation , menopause , attenuate use approve contraceptive method ( intrauterine device [ IUD ] , birth control pill , barrier device ) 3 month trial . If male , use approve contraceptive method study 3 month afterwards . Females childbearing potential must urine negative HCG test within 7 day prior study enrollment . No concomitant prescription include cyclosporin A , valproic acid , phenobarbital , phenytoin , ketoconazole . Non small cell lung cancer carcinoid Medically uncontrolled severe diarrhea recent three week . Inability comply protocol study procedure . Medically uncontrolled serious heart , lung , neurological , psychological , metabolic disease Second primary malignancy clinically detectable time consideration study enrollment . Pregnant breastfeeding . Enrollment study within 30 day Brain metastasis symptom</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>March 2016</verification_date>
	<keyword>Irinotecan ; Cisplatin ; Small-cell lung cancer ; UGT1A1</keyword>
</DOC>